Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema
- PMID: 18220146
- DOI: 10.1016/s1081-1206(10)60580-7
Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema
Abstract
Objective: To review the available evidence on the pathophysiologic mechanism of episodes of edema in hereditary angioedema (HAE).
Data sources: MEDLINE and PubMed were searched using the following keywords: hereditary angioedema, C1 inhibitor, complement system, contact system, and bradykinin.
Study selection: Studies were selected based on their relevance to the pathophysiologic features of HAE.
Results: Early studies from the 1970s and 1980s disagreed as to whether the symptoms in HAE were mediated via complement or contact system activation. Studies have demonstrated that, in vitro, in C1 inhibitor (C1-INH)-deficient plasma, only contact system activation results in generation of a vascular permeability enhancing factor. Furthermore, individuals who express a variant C1-INH that is a normal inhibitor of contact system proteases but is deficient in the ability to inactivate complement system proteases do not develop angioedema. The blood of patients with HAE, during attacks, contains elevated levels of cleaved high-molecular-weight kininogen and bradykinin. Last, C1-INH-deficient mice develop increased vascular permeability that is mediated via contact system activation.
Conclusions: Hereditary angioedema attacks are mediated by bradykinin generated via contact system activation. The specific factors that trigger attacks remain unclear.
Similar articles
-
Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment.Ann Med. 2016;48(4):256-67. doi: 10.3109/07853890.2016.1162909. Epub 2016 Mar 26. Ann Med. 2016. PMID: 27018196 Review.
-
Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis.Ann Allergy Asthma Immunol. 2010 Jan;104(1):50-4. doi: 10.1016/j.anai.2009.11.014. Ann Allergy Asthma Immunol. 2010. PMID: 20143645
-
High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency.Clin Exp Allergy. 2014 Dec;44(12):1503-14. doi: 10.1111/cea.12293. Clin Exp Allergy. 2014. PMID: 24552232
-
Hereditary angioedema: the plasma contact system out of control.J Thromb Haemost. 2018 Sep;16(9):1674-1685. doi: 10.1111/jth.14209. Epub 2018 Jul 17. J Thromb Haemost. 2018. PMID: 29920929 Review.
-
Hereditary angioedema: Pathophysiology (HAE type I, HAE type II, and HAE nC1-INH).Allergy Asthma Proc. 2020 Nov 1;41(Suppl 1):S14-S17. doi: 10.2500/aap.2020.41.200081. Allergy Asthma Proc. 2020. PMID: 33109319 Review.
Cited by
-
Hereditary Angioedema as a Metabolic Liver Disorder: Novel Therapeutic Options and Prospects for Cure.Front Immunol. 2016 Nov 30;7:547. doi: 10.3389/fimmu.2016.00547. eCollection 2016. Front Immunol. 2016. PMID: 27965672 Free PMC article.
-
Current management options for hereditary angioedema.Curr Allergy Asthma Rep. 2012 Aug;12(4):273-80. doi: 10.1007/s11882-012-0273-4. Curr Allergy Asthma Rep. 2012. PMID: 22729959 Review.
-
Erratum: Characteristics and Comorbidities Influencing Mortality Risk Among Hereditary Angioedema Patients.J Health Econ Outcomes Res. 2025 Aug 21;12(2):143450. doi: 10.36469/001c.143450. eCollection 2025. J Health Econ Outcomes Res. 2025. PMID: 40861016 Free PMC article.
-
Throat microbiota alterations in patients with hereditary angioedema.World Allergy Organ J. 2022 Sep 28;15(10):100694. doi: 10.1016/j.waojou.2022.100694. eCollection 2022 Oct. World Allergy Organ J. 2022. PMID: 36254183 Free PMC article.
-
The complement system: an evolution in progress.F1000Res. 2016 Dec 12;5:2840. doi: 10.12688/f1000research.10065.1. eCollection 2016. F1000Res. 2016. PMID: 27990282 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources